The Green Peak

Poseidon was founded by siblings Emily & Morgan Paxhia in 2013, making their first fund one of the longest-running dedicated cannabis investment funds, with over $105MM Assets Under Management and an IRR of 70% net of fees. The Poseidon team has focused on a diversified strategy covering a range of company stages and industry subsectors across the capital spectrum. Morgan Paxhia is a co-founder and Managing Partner of Poseidon, one of the longest-running funds in the cannabis industry.

European cannabis industry with Deepak Anand. Deepak is recognized as a thought leader in the global cannabis space. He currently serves as the co-founder and CEO of Materia Ventures, a European-focused supply and distribution company for medical cannabis and CBD products. He previously served as VP of business development and government relations at Cannabis Compliance Inc. as well as VP of Canadian licensed producer Zenabis. He is a board member for several for and not for profit cannabis businesses and industry associations across North America and Europe. In contrast to the North American cannabis markets, Materia Ventures believes that the European industry will develop to represent a highly regulated pharmaceutical-like market. Because the majority of global capital continues to be deployed towards cultivation assets, the dry flower will shift to become a raw input as opposed to a format of consumption. For this reason, Materia’s strategy is to conduct value-add downstream activities as opposed to cultivation; their core focuses will include extraction, processing and distribution.

Cannabis extract treatment protocols with Mara Gordon Co-founder / Chief Process Engineer of The Oil Plant (formerly Aunt Zelda’s). Mara Gordon specializes in the development of cannabis extract treatment protocols for seriously ill patients in California. She is the co-founder of Aunt Zelda’s and Zelda Therapeutics. Prior to Aunt Zelda’s, Mara worked as a process engineer, helping Fortune 500 companies create intelligent software by utilizing the Rational Unified Process. This experience has enabled her to take a detailed and scientific approach to medical cannabis. Recognizing a need for patient-focused software, Gordon founded CDRMed. With CDRMed, physicians and medical health professionals are able to make treatment recommendations based on the latest and highest-quality data. Gordon sits on the boards of Zelda Therapeutics, #illegallyhealed, and New Frontier. She has presented at multiple CME-accredited medical conferences, along with inaugural medical cannabis conferences in Australia, Costa Rica, Chile, and the Czech Republic, as well as other events throughout the United States.

California cannabis firms with Rob Hunt. Rob is a founding partner of Linnaea Holdings, a private equity firm that provides investments and operational expertise to California cannabis firms. Linnaea is a back-office solution play, where companies in the portfolio share office management like tax preparation and legal representation. This allows each company to double-down on what they do best, whether its cultivation, extraction, packaging, or retail sales, and ultimately allow Linnaea to create a vertically-integrated portfolio.

Cannabis venture capital fund with Ross O'Brien, Founder & CEO of Bonaventure Equity, LLC. Bonaventure Equity is a cannabis venture capital fund and runs the Cannabis Dealmakers Summit, a series of industry conferences and investment forums. Ross sits on the boards of the Green Ignition Ventures, Florida’s first cannabis accelerator, and CannaMexico and is author of “Cannabis Capital” the first book on cannabis venture capital for Entrepreneur Press. His broad spectrum of private company expertise ranges from starting and operating high growth businesses, to leading numerous Venture Capital, & Private Equity transactions, advising on Mergers & Acquisitions, raising capital and corporate finance internationally.

Quality & Compliance Services Inc with Kieran Tracey, Head Business Development and Aaron Clarke, director of. Kieran Tracey has more than fifteen years’ experience in digital health where he helped transform clinical and hospital-based care in Canada. During that time he worked with several start-up companies, a number of which were successful exits including Practice Solutions EMR to Telus Health and Privacy Analytics to IQVIA. His research interests include using machine learning to detect the early onset of diseases in intensive care units. Aaron Clarke: Since legalization, it's become clear that a strong quality function ensures success in the cannabis industry. In his leadership role at Q&C, Aaron Clarke has applied his pharmaceutical, food and water experience from the last 20 plus years, and, with a healthy dose of cultivation farm-boy know-how, provided expert quality solutions for clients entering the regulated cannabis sector, with a focus on those looking to export their products to international markets. His current responsibilities include solutions design, the establishment of GMP quality management systems, executive training, and keeping abreast of the ever-changing global regulations on behalf of his clients.

The way cannabis retailers manage compliance with Kyle Sherman is the Founder and CEO of Flowhub. A legalization advocate and entrepreneur, Kyle continually defines the company vision, strategy, and growth as Flowhub innovates the way cannabis retailers manage complex compliance mandates, supply chain data, sales transactions, and reporting. Kyle brings extensive cannabis industry experience to Flowhub, with previous experience working with notable brands such as Dixie Elixirs, Weedmaps, and Neos Vape Pens as a Chief Compliance Officer.

Organic cannabis extracts with Jon Ruiz Executive President & CEO, Medcann. Medcann's raison d'être is to produce 100% organic cannabis extracts certified for medicinal use, in an innovative, responsible and sustainable manner. They ensure the highest quality for the development of therapeutic solutions that contribute to improving people’s lives around the world. Medcann aspires to become the largest and most cost-effective operator of outdoor medicinal cannabis and one of the largest gene banks in the world. Their aim is to add value to society by promoting research, development, and access to efficient cannabis-based therapeutic solutions for patients that may benefit from their use. To achieve the purpose Medcann believes in working jointly with health professionals, patients, governments, patient organizations, technology partners and investors.

Medical Cannabis In Peru with Rafael Canovas Newell, Plena Global's Director of Government Affairs & Partnerships in South America. The government of Peru published the regulations that will govern both the application and production of medical cannabis inside the country. These regulations are among the most developed in any market globally, and enable Peru to position itself as a leading cultivator and supplier for the world market, while simultaneously providing effective, low-cost treatment to Peruvians dealing with a broad variety of conditions. In the lead-up to this historic announcement, Peruvian officials have been working with scientists, doctors, and the Canadian medical marijuana company Plena Global Holdings to ensure the country can benefit from an effective transition to a regulated industry that operates at the highest standards of medical cannabis regulation worldwide. The extended period of time between the signing of the law legalizing medical cannabis, and the adoption of the regulatory framework overnight, was effectively used by the government of Peru to ensure a thorough framework for industry operations was established.

Expand the potential for medicine with Brent Zettl, President & Chief Executive Officer of ZYUS. Zettl, BSA Distinction (Agriculture), is the leading pioneer of the Canadian medical cannabis industry and has led many of Canada’s significant advancements in patient care and cannabis clinical research. He founded Prairie Plant Systems Inc. in 1988 which eventually became the sole provider of legal medical cannabis products to Health Canada through the years 2000 to 2013. In 2017, PPS combined with CanniMed Therapeutics to list on TSX. In March 2018, CanniMed was acquired by Aurora Cannabis Inc. for CAD$1.1-billion. Advancements in biopharmaceuticals are dramatically improving health outcomes and transforming our expectations of disease. Despite successful treatment, however, people continue to suffer from pain and discomfort due to chronic disease, treatment side effects or conditions related to aging. ZYUS was founded by Brent Zettl and his industry-leading senior management team from the medicinal cannabis sector, who have a collective clear purpose to expand the potential for medicine by advancing the science of well-being. The ZYUS Vision: To forge a new industry of phytotherapeutics and elevate its solutions as a standard of care for treating disease and managing the experience of it. ZYUS is upgrading a global-scale ethanol extraction facility that will source dry herbal feedstock cannabis material from multiple Canadian licensed cannabis producers (LPs), thereby taking advantage of a dry herbal capacity overbuild widely anticipated to emerge within the next one to two years. ZYUS is solely focused on the development of pharmaceutical-grade medicinal oil products and dedicated to improving patient well-being, which is highly unique and well placed relative to the overall direction of the domestic and global industry. The timing for ZYUS’s business plan is particularly attractive due to a number of industry trends and indicators. Cannabis oil and oil derivative products are poised to become the majority of the domestic and global cannabis markets. These markets are anticipated to grow rapidly over the next ten years. These value-added oil products require a high level of expertise to successfully establish commercial extraction facilities and produce pharmaceutical-grade cannabinoid formulations on the scale.